A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety, Efficacy, and Pharmacokinetics of the Fixed Combination of AGN-199201 and AGN-190584 in Patients With Presbyopia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs AGN 190584 (Primary) ; Oxymetazoline (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors Allergan
- 04 Oct 2017 Planned End Date changed from 4 Jan 2018 to 27 Oct 2017.
- 04 Oct 2017 Planned primary completion date changed from 4 Jan 2018 to 27 Oct 2017.
- 04 Oct 2017 Status changed from recruiting to active, no longer recruiting.